Helomics
Headquartered in Pittsburgh, Helomics is a division of Predictive Oncology Inc. Our mission is to improve outcomes for current and future cancer patients using a knowledge and AI-driven approach. We leverage our proprietary tumor profiling platform, a vast historical knowledgebase of 150K+ de-identified patient drug response profiles together with proven AI to deliver more precisely targeted therapies for patients.
15+
Years of outcome data
137
Tumor types
150K+
Tumors
Let us tell you about Helomics.
Helomics has a key proprietary technology platform and data pipeline that provides next-generation, AI- and data-driven services to Pharma and Diagnostic companies to accelerate the development of new precision therapies.
For BioPharma, Helomics improves the efficiency and cost effectiveness of the discovery of new drugs. For Clinicians, Helomics helps oncologists to individualize current therapies for patients.
Clinical
Testing
Helomics helps to personalize patient therapies
Drug
Discovery
Helomics database of 150K+ tumors aids in reducing discovery timeline
Oncology
Research
TumorGenesis develops living tumors outside the body for study and testing
Drug
Development
Soluble Biotech supplies formulations for delivery of therapeutics and vaccines
Cell
Cultures
zPREDICTA utilizes tumor-specific 3D cell culture models, enabling more successful drug development